Rhythm Biosciences (ASX:RHY) has launched its updated geneType colorectal cancer risk assessment test, integrating genetic, clinical, and lifestyle factors to improve early identification of individuals at elevated risk of colorectal cancer.
The enhanced test builds on the company’s established 140-SNP polygenic risk score and introduces gender-specific variables, delivering stronger predictive accuracy for both men and women, including younger adults.
Peer-reviewed validation published in PLOS ONE (Dite GS, et al., 2025) confirms the updated model outperforms traditional approaches.
By factoring in lifestyle risks, which contribute to approximately 50% of CRC cases, the test aims to support earlier intervention through targeted screening and complement Rhythm’s ColoSTAT blood-based CRC detection.